Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Analysts warn that these tariffs could lead to higher production costs, reduced profitability, and even drug shortages. As Trump’s tariff threats loom, investors are left questioning whether to hold ...

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing ...

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...